Sugi Predict

Sugi Predict / Compounds / SCHEMBL3092467

SCHEMBL3092467

SCHEMBL3092467

COC(=O)[C@H](C(C)C)N(C)S(=O)(=O)c1ccc(Br)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS4 O75173 1/20 0.51
▸ MMP9 P14780 9/20 0.48
▸ MMP1 P03956 7/20 0.48
▸ MMP13 P45452 7/20 0.48
▸ ADAM17 P78536 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ KMT2A Q03164 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ MMP2 P08253 10/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ MMP3 P08254 5/20 0.41
▸ MMP7 P09237 4/20 0.41
▸ MMP14 P50281 2/20 0.41
▸ MMP16 P51512 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ MMP12 P39900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27784184 1.00 ADAMTS4 (0.51) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL6501034 0.87 ADAMTS4 (0.52) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL6505810 0.86 ADAMTS4 (0.51) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL3620444 0.82 ADAMTS4 (0.58) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL3082275 0.82 ADAMTS4 (0.58) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL3613169 0.82 ADAMTS4 (0.58) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL7533774 0.80 MMP9 (0.64) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL7533771 0.80 MMP9 (0.64) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL3099546 0.79 ADAMTS4 (0.54) ADAMTS4MMP9MMP1MMP13ADAM17
SCHEMBL3610021 0.79 ADAMTS4 (0.54) ADAMTS4MMP9MMP1MMP13ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567345-B2 Pharmaceutically active pyrazolo-triazine derivatives LEAD DISCOVERY CENTER GMBH (DE) 2017-02-14 — — US claimed
EP-2820020-B1 PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2016-04-06 — — EP claimed
US-9096608-B2 Pharmaceutically active pyrazolo-triazine derivatives LEAD DISCOVERY CENTER GMBH (DE) 2015-08-04 — — US claimed
US-20150111873-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2015-04-23 — — US claimed
WO-2013128029-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2013-09-06 — — WO claimed
EP-2634190-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors Lead Discovery Center GmbH (DE) 2013-09-04 — — EP claimed
EP-2634189-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors Lead Discovery Center GmbH (DE) 2013-09-04 — — EP claimed
CN-118355128-A Method for capturing library DNA for sequencing 因美纳有限公司 2024-07-16 — — CN disclosed
CN-118265720-A Compositions and methods for treating metabolic disorders and liver diseases 维京治疗公司 2024-06-28 — — CN disclosed
CN-118251134-A Amide compounds and their use as flavor modifiers 弗门尼舍公司 2024-06-25 — — CN disclosed
CN-117916390-A Compositions and methods for sequencing-by-synthesis 伊鲁米纳公司 2024-04-19 — — CN disclosed
CN-117677435-A Surface functionalization of non-aqueous gels for sequencing 伊鲁米纳公司 2024-03-08 — — CN disclosed
CN-117402189-A Phosphoramidate (phosphonate) acetals and phospho (phosphonate) acetal compounds 广东集宝医药技术有限公司 2024-01-16 — — CN disclosed
EP-1912634-A2 PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Healthcare, LLC (US) 2008-04-23 — — EP disclosed
WO-2007060220-A2 CYANOBENZENE COMPOUNDS FOR COMBATING ANIMAL PESTS BASF SE (DE) 2007-05-31 — — WO disclosed
WO-2007016538-A2 PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2007-02-08 — — WO disclosed
WO-2007016538-A2 PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2007-02-08 — — WO disclosed
EP-1503761-A1 SUBSTITUTED PIPERAZINES AS MELANOCORTIN RECEPTOR LIGANDS Neurocrine Biosciences, Inc. (US) 2005-02-09 — — EP disclosed
US-20040053933-A1 Ligands of melanocortin receptors and compositions and methods related thereto NEUROCRINE BIOSCIENCES, INC. 2004-03-18 — — US disclosed
WO-2003094918-A1 SUBSTITUTED PIPERAZINE AS MELANOCORTIN RECEPTORS LIGANDS NEUROCRINE BIOSCIENCES, INC. (US) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053933-A1 Ligands of melanocortin receptors and compositions and methods related thereto MC3R, MC1R, MC5R ADAMTS4 3123/4885MMP9 4084/4885MMP1 4474/4885
US-20150111873-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES PAK5, STK35, TESK2 ADAMTS4 2860/4885MMP9 3436/4885MMP1 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.